COVID-19 vaccines


  • Updated schedule for the period 22-25 April vaccination program against COVID-19 , 21-04-2021
  • COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets , 20-04-2021
  • The implementation of the National Vaccination Plan continues – Appointments available for individuals aged 51-52 , 18-04-2021
  • Press conference on the next steps of the vaccination plan , 16-04-2021
  • 200,000 vaccinations administered in Cyprus until today – Priority to 53-54 age group for vaccination appointments on 16-17 April , 15-04-2021
  • Janssen vaccine will not be administered pending the completion of the investigation of thrombosis cases in the USA , 14-04-2021
  • AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets , 14-04-2021
  • No self-isolation required for close contacts who have been vaccinated , 14-04-2021
  • General instructions to persons vaccinated - Janssen (Johnson&Johnson) Vaccine , 14-04-2021
  • Requests for the COVID-19 home vaccination of bedridden individuals end on 16 April , 13-04-2021
  • Vaccination appointment programme for the period 13-17 April , 12-04-2021
  • Vaccination portal opens on Sunday for individuals belonging to specific vulnerable groups , 10-04-2021
  • Access to the Vaccination Portal for the arrangement of appointments by individuals aged 59 and 60 , 09-04-2021
  • AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets , 07-04-2021
  • 19,378 appointments to be made available for the vaccination of persons aged 61 and over , 06-04-2021
  • Vaccination Portal opens for individuals who use biological agents or other immunosuppressive medicines , 04-04-2021
  • AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues , 31-03-2021
  • Vaccination Portal to be made available for people aged 64 and over, on 1 April , 31-03-2021
  • Vaccination Portal available until 31 March for patients with Diabetes Mellitus and Severe Obesity , 31-03-2021
  • Over 19,000 vaccination appointments for individuals with Diabetes Mellitus and Severe Obesity , 28-03-2021
  • Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna , 26-03-2021
  • COVID-19 Vaccine AstraZeneca – Update on ongoing evaluation of blood clot cases , 26-03-2021
  • A total of 310,000 individuals will have received at least the 1st dose of a vaccine by the beginning of May , 22-03-2021
  • Rescheduling of postponed appointments for vaccination with the AstraZeneca vaccine , 21-03-2021
  • The Vaccination Portal will be made available for people aged 66 and over on 20 – 21 March , 19-03-2021
  • AstraZeneca vaccinations to be carried out normally , 18-03-2021
  • COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets , 18-03-2021
  • Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues , 16-03-2021
  • Postponement of vaccinations with the AstraZeneca vaccine until 18 March , 15-03-2021
  • EMA’s Safety Committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events – further update , 15-03-2021
  • Answers to frequently asked questions on COVID-19 Vaccine Janssen , 11-03-2021
  • EMA recommends COVID-19 Vaccine Janssen (Johnson&Johnson) for authorisation in the EU , 11-03-2021
  • COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria , 11-03-2021
  • Vaccination Portal to be made available for people aged 67 and over – 22,808 vaccination appointments , 08-03-2021
  • EMA starts rolling review of the Sputnik V COVID-19 vaccine , 04-03-2021
  • Vaccination Portal to be made available for people aged 69 and over – 17,496 vaccination appointments , 02-03-2021
  • The objectives of the National Vaccination Plan are being achieved – More than 64,000 vaccines have been administered by the 23rd February , 24-02-2021
  • As of 23 February, 16,904 vaccination appointments will be made available for people aged 71 and over , 22-02-2021
  • COVID-19 Vaccination of specific categories of the population based on serious illness risk factors , 19-02-2021
  • National Vaccination Plan for COVID-19: 9.096 appointments for persons aged 74 and over , 16-02-2021
  • Statement by the Minister of Health, Mr Constantinos Ioannou, at the press conference on the National Vaccination Plan for COVID-19 , 12-02-2021
  • EMA starts rolling review of CureVac’s COVID-19 vaccine (CVnCoV) , 12-02-2021
  • 9,264 Vaccination appointments made available for people over the age of 76 , 11-02-2021
  • Clarifications regarding the administration of AstraZeneca vaccine to specific age groups , 10-02-2021
  • Third phase of the National Vaccination Plan for COVID-19 begins with appointments made available for people over the age of 79 , 09-02-2021
  • General instructions to persons vaccinated - AstraZeneca Vaccine , 09-02-2021
  • EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373) , 04-02-2021
  • Vaccination Portal to be made available to citizens over the age of 83 , 02-02-2021
  • Vaccination appointments for citizens over the age of 84 – 7,790 vaccine doses administered during the week of 23-29 January , 30-01-2021
  • EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU , 29-01-2021
  • Answer to frequently-asked questions on COVID-19 Vaccine AstraZeneca , 29-01-2021
  • COVID-19 vaccine safety update for Comirnaty , 29-01-2021
  • First COVID-19 vaccine safety update published , 29-01-2021
  • Clarification of Comirnaty dosage interval , 29-01-2021
  • Vaccination Portal to be made available to citizens over the age of 86 as of 29 January – New appointments as of 1st February , 28-01-2021
  • Vaccination Portal to be made available to citizens over the age of 88 as of 27 January , 26-01-2021
  • General instructions to persons vaccinated - Moderna Vaccine , 13-01-2021
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca , 12-01-2021
  • EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU , 06-01-2021
  • Answers to frequently asked questions on COVID-19 Vaccine Moderna , 06-01-2021
  • GHS Beneficiary Portal User Manual for COVID-19 Vaccination , 04-01-2021
  • Application process for the registration to Covid-19 Vaccinations’ Portal of citizens who are not GHS beneficiaries , 04-01-2021
  • Document for the Registration of Citizens who are not GHS beneficiaries, to the Cyprus Portal for COVID-19 vaccinations , 04-01-2021
  • Update on rolling review of AstraZeneca’s COVID-19 vaccine , 31-12-2020
  • General instructions to persons vaccinated - Comirnaty (Pfizer/BioNTeck) Vaccine , 28-12-2020
  • First batch of Pfizer-BioNTech vaccines to be delivered on 26 December – vaccinations to begin on 27 December , 22-12-2020
  • Answers to frequently asked questions about Comirnaty - COVID-19 mRNA vaccine (nucleoside modified) , 22-12-2020
  • EMA recommends first COVID-19 vaccine for authorisation in the EU , 21-12-2020
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application , 16-12-2020
  • Answers to frequently asked questions about vaccines/vaccination against COVID-19 , 15-12-2020
  • The National Vaccination Plan for COVID-19 was presented , 15-12-2020
  • National Vaccination Plan for Covid-19 , 15-12-2020